Common use of Royalty Rates Clause in Contracts

Royalty Rates. As further consideration for the rights granted to AbbVie hereunder, subject to Section 6.7.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory, on a Licensed Product-by-Licensed Product basis, AbbVie shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during each Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Territory of each Licensed Product containing the same Licensed Compound in a Calendar Year Royalty Rate For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year equal to or less than [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] but equal to or less than [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] [*] The royalty tiers set forth in the table above shall only aggregate Licensed Products that contain the same Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Licensed Compound in the Territory during a Calendar Year are [*], and Net Sales for all Licensed Products containing a different Licensed Compound in the Territory during such Calendar Year are [*], then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [*]. With respect to each Licensed Product in each country or other jurisdiction in the Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country or other jurisdiction, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in this Section 6.7.1.

Royalty Rates. As further consideration for Subject to the rights granted to AbbVie hereunder, subject to remainder of this Section 6.7.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory9.3, on a Licensed Product-by-Licensed Product and country-by-country basis, AbbVie shall Ultragenyx will pay to Licensor a royalty Solid royalties based on the aggregate Net Sales of each the applicable Licensed Product (whether or not an Initial Licensed Product or sold by a Follow-On Product) Selling Party during a Calendar Year at the rates set forth in the Territory (excluding applicable table below; provided that in no event will royalties be due with respect to Net Sales of each Licensed an Income Share Product in any country or other jurisdiction the Option Territory even if a Product Reversion occurs with respect to such Income Share Product. The obligation to pay royalties will be imposed only once with respect to the same unit of a Licensed Product. 36 Calendar Year Net Sales (in the Territory for which the Royalty Term U.S. Dollars) for such Licensed Product in such country or other jurisdiction has expiredRoyalty Rates as a Percentage (%) during each of Net Sales with respect to a Licensed Product that is not an Option Product Royalty Rates as a Percentage (%) of Net Sales with respect to a Development Share Product Portion of Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Territory of each Licensed Product containing the same Licensed Compound in a Calendar Year Royalty Rate For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year equal up to or less than and including $[**] [*] For that portion *]% [**]% Portion of aggregate Calendar Year Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than that exceeds $[**] but equal up to or less than and including $[**] [*] For that portion *]% [**]% Portion of aggregate Calendar Year Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than that exceeds $[**] [**]% [**]% Calendar Year Net Sales (in U.S. Dollars) for such Licensed Product that is an Income Share Product outside the Option Territory Royalty Rates as a Percentage (%) of Net Sales with respect to an Income Share Product Portion of Calendar Year Net Sales up to and including $[**] The [**]% Portion of Calendar Year Net Sales that exceeds $[**] up to and including $[**] [**]% Portion of Calendar Year Net Sales that exceeds $[**] [**]% On a Licensed Product-by-Licensed Product basis, Net Sales of an Income Share Product in the Option Territory will not be counted for purposes of determining which royalty tiers tier applies to the Net Sales of such Income Share Product outside the Option Territory. Further, the applicable royalty rate set forth in the applicable table above shall will apply only aggregate to that portion of the Net Sales of a given Licensed Products Product during a given Calendar Year that contain falls within the same Licensed Compoundsindicated range. For exampleBy way of example and without limitation of this Section 9.3.1, if Calendar Year Net Sales for all by the Selling Parties of a given Licensed Products containing the same Licensed Compound in the Territory during a Calendar Year are Product that is not an Option Product were [**] Dollars ($[**]) for a given Calendar Year, and Net Sales for all Licensed Products containing a different Licensed Compound in then the Territory during royalties payable with respect to such Calendar Year are [*], then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [*]. With respect to each Licensed Product in each country or other jurisdiction in the Territory, from and after the expiration of the Royalty Term for such Licensed Product in for such country or other jurisdictionCalendar Year, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings subject to adjustment as set forth in this Section 6.7.19.3.1, would be: [**].

Royalty Rates. As further consideration for the rights granted to AbbVie Licensee hereunder, subject to Section 6.7.35.10.3 and Section 6.2.3, commencing upon the First date of the first Commercial Sale of a Licensed Product in the Licensee Territory, on a Licensed Product-by-Licensed Product basis, AbbVie Licensee shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Licensee Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Licensee Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during each Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Licensee Territory of each all Licensed Product containing Products Containing the same Same Licensed Compound in a Calendar Year Royalty Rate For that portion of aggregate Net Sales of each all Licensed Product Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year less than $[***] [***] % For that portion of aggregate Net Sales of all Licensed Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year equal to or greater than $[***] but less than $[***] [***] % For that portion of aggregate Net Sales of each all Licensed Product Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year greater than [*] but equal to or less greater than $[***] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [**] [*] % The royalty tiers set forth in the table above shall only aggregate apply separately to Licensed Products that contain the same different Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Initial Licensed Compound in the Licensee Territory during a Calendar Year are $[***], and Net Sales during for all Licensed Products containing a Licensed Compound different from the Initial Licensed Compound in the Licensee Territory during such Calendar Year are $[***], then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [***]%. With respect to each Licensed Product in each country or other jurisdiction in the Licensee Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country or other jurisdictioncountry, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in this Section 6.7.16.2.1.

Royalty Rates. As further consideration for the rights granted to AbbVie Licensee hereunder, subject to Section 6.7.35.10.3 and Section 6.2.3, commencing upon the First date of the first Commercial Sale of a Licensed Product in the Licensee Territory, on a Licensed Product-by-Licensed Product basis, AbbVie Licensee shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Licensee Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Licensee Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during each Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Licensee Territory of each all Licensed Product containing Products Containing the same Same Licensed Compound in a Calendar Year Royalty Rate For that portion of aggregate Net Sales of each all Licensed Product Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year less than $3,000,000,000 20 % For that portion of aggregate Net Sales of all Licensed Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year equal to or greater than $3,000,000,000 but less than [*] [*] $5,000,000,000 24 % For that portion of aggregate Net Sales of each all Licensed Product Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year greater than [*] but equal to or less greater than $5,000,000,000 28 % Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] [*] ]. The royalty tiers set forth in the table above shall only aggregate apply separately to Licensed Products that contain the same different Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Initial Licensed Compound in the Licensee Territory during a Calendar Year are [*]$2,000,000,000, and Net Sales during for all Licensed Products containing a Licensed Compound different from the Initial Licensed Compound in the Licensee Territory during such Calendar Year are [*]$2,500,000,000, then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [*]20%. With respect to each Licensed Product in each country or other jurisdiction in the Licensee Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country or other jurisdictioncountry, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in this Section 6.7.16.2.1.

Royalty Rates. As further consideration for the rights granted to AbbVie Licensee hereunder, subject to Section 6.7.35.10.3 and Section 6.2.3, commencing upon the First date of the first Commercial Sale of a Licensed Product in the Licensee Territory, on a Licensed Product-by-Licensed Product basis, AbbVie Licensee shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Licensee Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Licensee Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during each Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Licensee Territory of each all Licensed Product containing Products Containing the same Same Licensed Compound in a Calendar Year Royalty Rate For that portion of aggregate Net Sales of each all Licensed Product Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year less than $3,000,000,000 20 % For that portion of aggregate Net Sales of all Licensed Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year equal to or greater than $3,000,000,000 but less than [*] [*] $5,000,000,000 24 % For that portion of aggregate Net Sales of each all Licensed Product Products containing the same Licensed Compound in the Licensee Territory during a Calendar Year greater than [*] but equal to or less greater than $5,000,000,000 28 % Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [*] [*] For that portion *]. An unredacted version of aggregate Net Sales of each Licensed Product containing this exhibit has been separately filed with the same Licensed Compound in the Territory during a Calendar Year greater than [*] [*] Securities and Exchange Commission. The royalty tiers set forth in the table above shall only aggregate apply separately to Licensed Products that contain the same different Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Initial Licensed Compound in the Licensee Territory during a Calendar Year are [*]$2,000,000,000, and Net Sales during for all Licensed Products containing a Licensed Compound different from the Initial Licensed Compound in the Licensee Territory during such Calendar Year are [*]$2,500,000,000, then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [*]20%. With respect to each Licensed Product in each country or other jurisdiction in the Licensee Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country or other jurisdictioncountry, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in this Section 6.7.16.2.1.

Royalty Rates. As further consideration for Subject to the rights granted to AbbVie hereunder, subject to other terms of this Section 6.7.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory5.4, on a Licensed Product-by-Licensed Product basis, AbbVie shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Territory for which during the Royalty Term for such Licensed a given Product in such a given country or other jurisdiction has expired) during each in the Royalty Bearing Territory, Merck shall make, on a Calendar Year basis, royalty payments to NewLink on the Product Net Sales of such Product in a given Calendar Year in such countries at the following rates: [ applicable royalty rate set forth below (which royalty rates shall be different for the Current Product and for any other Product as set forth below). For clarity, the royalties (and royalty tiers) shall be calculated separately on a Product-by-Product basis. Current Product Annual Product Net Sales of a given Product in the Royalty-Bearing Territory in a given Calendar Year Royalty Rate for Product Net Sales Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory up to and including $[**] in a given Calendar Year [**]% [**] = Certain confidential information contained in this document, marked by brackets, is has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 24b-2 of the Securities Exchange Act of 19331934, as amended. Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory of each Licensed Product containing the same Licensed Compound greater than $[**] and less than or equal to $[**] in a given Calendar Year [**]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[**] and less than or equal to $[**] in a given Calendar Year [**]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[**] in a given Calendar Year [**]% Products other than Current Product Annual Product Net Sales of a given Product in the Royalty-Bearing Territory in a given Calendar Year Royalty Rate For that portion of aggregate for Product Net Sales Portion of each Licensed annual Product containing the same Licensed Compound in the Territory during a Calendar Year equal to or less than [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] but equal to or less than [*] [*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater than [*] [*] The royalty tiers set forth in the table above shall only aggregate Licensed Products that contain the same Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Licensed Compound a given Product in the applicable countries in the Royalty Bearing Territory during up to and including $[**] in a given Calendar Year are [**], and % Portion of annual Product Net Sales for all Licensed Products containing a different Licensed Compound given Product in the applicable countries in the Royalty Bearing Territory during such greater than $[**] and less than or equal to $[**] in a given Calendar Year are [**], then all such % Portion of annual Product Net Sales for both sets of Licensed Products during such a given Product in the applicable countries in the Royalty Bearing Territory greater than $[**] and less than or equal to $[**] in a given Calendar Year shall bear a royalty rate of [**]. With respect to each Licensed % Portion of annual Product Net Sales for a given Product in each country or other jurisdiction the applicable countries in the TerritoryRoyalty Bearing Territory greater than $[**] in a given Calendar Year [**]% For clarity, from and after the expiration (i) if no royalty is payable on a given unit of Product (e.g., following the Royalty Term for such Licensed Product in such a given country or other jurisdictionsales of a given Product outside of the Royalty Bearing Territory), then the Product Net Sales of such Licensed unit of Product in such country or other jurisdiction shall not be excluded included for purposes of calculating determining the foregoing royalty tiers and (ii) Product Net Sales thresholds and ceilings set forth of a given Product will not be combined with [**] = Certain confidential information contained in this Section 6.7.1document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Product Net Sales of any other Product for purposes of determining the foregoing royalty tiers.

Royalty Rates. As further consideration for Subject to the rights granted to AbbVie hereunder, subject to other terms of this Section 6.7.3, commencing upon the First Commercial Sale of a Licensed Product in the Territory5.4, on a Licensed Product-by-Licensed Product basis, AbbVie shall pay to Licensor a royalty on Net Sales of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Territory for which during the Royalty Term for such Licensed a given Product in such a given country or other jurisdiction has expired) during each in the Royalty Bearing Territory, Merck shall make, on a Calendar Year basis, royalty payments to NewLink on the Product Net Sales of such Product in a given Calendar Year in such countries at the following rates: [ applicable royalty rate set forth below (which royalty rates shall be different for the Current Product and for any other Product as set forth below). For clarity, the royalties (and royalty tiers) shall be calculated separately on a Product-by-Product basis. Current Product Annual Product Net Sales of a given Product in the Royalty-Bearing Territory in a given Calendar Year Royalty Rate for Product Net Sales Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory up to and including $[*] = in a given Calendar Year [*]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[*] and less than or equal to $[*] in a given Calendar Year [*]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[*] and less than or equal to $[*] in a given Calendar Year [*]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[*] in a given Calendar Year [*]% Products other than Current Product [*] Certain confidential information contained in this document, marked by brackets, is has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 24b-2 of the Securities Exchange Act of 19331934, as amended. Annual Product Net Sales of a given Product in the Royalty-Bearing Territory of each Licensed Product containing the same Licensed Compound in a given Calendar Year Royalty Rate For that portion of aggregate for Product Net Sales Portion of each Licensed annual Product containing the same Licensed Compound Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory during a Calendar Year equal up to or less than and including $[*] in a given Calendar Year [*]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[*] For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year greater and less than or equal to $[*] but equal to or less in a given Calendar Year [*]% Portion of annual Product Net Sales for a given Product in the applicable countries in the Royalty Bearing Territory greater than $[*] and less than or equal to $[*] For that portion in a given Calendar Year [*]% Portion of aggregate annual Product Net Sales of each Licensed for a given Product containing the same Licensed Compound in the applicable countries in the Royalty Bearing Territory during a Calendar Year greater than $[*] [*] The royalty tiers set forth in the table above shall only aggregate Licensed Products that contain the same Licensed Compounds. For example, if Net Sales for all Licensed Products containing the same Licensed Compound in the Territory during a given Calendar Year are [*]% For clarity, and Net Sales for all Licensed Products containing (i) if no royalty is payable on a different Licensed Compound in the Territory during such Calendar Year are [*]given unit of Product (e.g., then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [*]. With respect to each Licensed Product in each country or other jurisdiction in the Territory, from and after the expiration of following the Royalty Term for such Licensed Product in such a given country or other jurisdictionsales of a given Product outside of the Royalty Bearing Territory), then the Product Net Sales of such Licensed unit of Product in such country or other jurisdiction shall not be excluded included for purposes of calculating determining the foregoing royalty tiers and (ii) Product Net Sales thresholds and ceilings set forth in this Section 6.7.1of a given Product will not be combined with Product Net Sales of any other Product for purposes of determining the foregoing royalty tiers.

Royalty Rates. As In further consideration for the licenses and other rights granted to AbbVie hereunderAcadia herein by Stoke, subject to the remainder of this Section 6.7.39.2(c), commencing upon Acadia shall make quarterly non-refundable, non-creditable royalty payments to Stoke on the First Commercial Sale aggregate Net Sales, on a MECP2 Licensed Product-by- MECP2 Licensed Product basis, sold in the Territory in a given Calendar Year, calculated by multiplying the applicable royalty rate set forth below by such Net Sales. The applicable royalty rates set forth in the table below will apply only to that portion of the Net Sales during a given Calendar Year that falls within the indicated range. Net Sales of each MECP2 Licensed Product throughout the Territory will be aggregated for purposes of determining the royalty tiers and royalties, provided that if no royalty is payable on a given unit of MECP2 Licensed Product (i.e., following the expiration of the MECP2 Royalty Term for such MECP2 Licensed Product in a given country), then the Net Sales of such unit of MECP2 Licensed Product shall not be included in Net Sales for purposes of determining the royalty tiers and royalties due hereunder. All royalty payments, and associated reports, shall be made in accordance with Section 9.7(c). Aggregate Annual Net Sales of a MECP2 Licensed Product in the Territory, on a Licensed Product-by-Licensed Product basis, AbbVie shall pay to Licensor a royalty on Net Sales Territory Royalty Rate Portion of each Licensed Product (whether or not an Initial Licensed Product or a Follow-On Product) in the Territory (excluding Net Sales of each Licensed Product in any country or other jurisdiction in the Territory for which the Royalty Term for such Licensed Product in such country or other jurisdiction has expired) during each Calendar Year at the following rates: [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Net Sales in the Territory of each Licensed Product containing the same Licensed Compound in a given Calendar Year Royalty Rate For that portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a Calendar Year less than or equal to or less than [***] [***] For that portion Portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a given Calendar Year greater than [***] but less than or equal to or less than [***] [***] For that portion Portion of aggregate Net Sales of each Licensed Product containing the same Licensed Compound in the Territory during a given Calendar Year greater than [***] but less than or equal to ***] [***] The royalty tiers set forth in the table above shall only aggregate Licensed Products that contain the same Licensed Compounds. For example, if Portion of Net Sales for all Licensed Products containing the same Licensed Compound in the Territory during a given Calendar Year are greater than [*], and Net Sales for all Licensed Products containing a different Licensed Compound in the Territory during such Calendar Year are **] [*], then all such Net Sales for both sets of Licensed Products during such Calendar Year shall bear a royalty rate of [**]. With respect to each Licensed Product in each country or other jurisdiction in the Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country or other jurisdiction, Net Sales of such Licensed Product in such country or other jurisdiction shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in this Section 6.7.1.